FDA Extends LDT Comment Period | GenomeWeb

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has reopened its comment period for the public and stakeholders to respond to its oversight plans for laboratory-developed tests until September 15.

FDA reopened the comment period, which initially closed on August 15, because it had received requests from stakeholders who wanted more time to develop or provide their opinions and recommendations on the issue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.